[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Azerbaijan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,68,91,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100651609","phase-2-surgical-treatment-for-gingival-recessions-after-orthodontic-treatment-100651609",false,"NCT07763808","Surgical Treatment for Gingival Recessions After Orthodontic Treatment","Improvement of Surgical Approaches for the Management of Gingival Recessions in Patients After Orthodontic Treatment","Inclusion Criteria:\n\n* Systemically healthy patients\n* RT1 and RT2 gingival recession defects according to the Cairo classification, with recession depth ≥ 2 mm\n* Completed orthodontic treatment\n* Aged between 18 and 70\n\nExclusion Criteria:\n\n* Smokers\n* Pregnancy\n* Poor adherence to oral hygiene practices\n* Refusal to participate in the study",true,"ALL","18 Years","70 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","Modification of the periodontal soft tissue phenotype and coverage of exposed root surfaces in patients who have undergone orthodontic treatment.",[29],"Gingival Recessions, Generalized","RECRUITING","2026-08-09",{"date":33,"type":34},"2026-08-13","ACTUAL",{"date":36,"type":22},"2026-09-01",{"date":38,"type":22},"2027-11-01",{"name":40,"class":41},"Aziz Aliyev Azerbaijan State Advanced Training Institute for Doctors","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100339167","efficacy-safety--utilisation-of-nuwiq-octanate-and-wilate-in-previously-untreated--minimally-treated-haemophilia-a-patients-100339167","NCT03695978","Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated & Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment With Nuwiq, Octanate or Wilate - Efficacy & Safety Observational Study-Protect-NOW","Protect-NOW","Inclusion Criteria:\n\n* Male and female patients of any age and ethnicity\n* Severe haemophilia A (FVIII:C\\\u003C1%)\n* Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study\n* Either\n* No previous treatment with FVIII concentrates or other blood products containing FVIII (PUPs) OR\n* Less than 5 Exposure Days (EDs) to FVIII concentrates or other blood products containing FVIII (MTPs), if\n* data are available on all previous treatment, AND\n* they did not develop an inhibitor at any time point, OR\n* they developed an inhibitor during treatment with an Octapharma FVIII concentrate AND continue treatment with THIS Octapharma FVIII concentrate (in the presence or absence of emicizumab).\n* Voluntarily given, fully informed written and signed consent obtained before any study-related data documentation is conducted (obtained from the patient's parent\u002Flegal guardian)\n\nExclusion Criteria:\n\n* Diagnosis with a coagulation disorder other than haemophilia A\n* Concomitant treatment with any systemic immunosuppressive drug\n* Participation in an interventional clinical trial during the time period evaluated\n* Participation in another non-interventional study of Octapharma",{"count":52,"type":22},200,"OBSERVATIONAL","International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.",[56],"Haemophilia A","2026-05-29",{"date":59,"type":34},"2026-06-02",{"date":61,"type":34},"2018-02-13",{"date":63,"type":22},"2030-06",{"name":65,"class":66},"Octapharma","INDUSTRY",59,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100627327","investigation-of-pain-perception-according-to-gender-in-individuals-with-scoliosis-100627327","NCT07447193","Investigation of Pain Perception According to Gender in Individuals With Scoliosis","Inclusion Criteria:\n\n* Having a clinical or radiological diagnosis of scoliosis\n* Being between 18-45 years of age\n* Not having undergone scoliosis surgery in the last 6 months\n* Agreeing to participate in the study voluntarily\n\nExclusion Criteria:\n\n* Having a history of neurological disease\n* Acute inflammatory spinal disease\n* Serious cardiovascular or systemic diseases that would prevent participation in exercise","45 Years",{"count":76,"type":22},50,[78],"NA","The aim of this study is to evaluate whether pain perception under spinal pressure created on a physiotherapy roller differs according to gender in individuals diagnosed with scoliosis.",[81],"Scoliosis","2026-04-03",{"date":84,"type":34},"2026-04-09",{"date":86,"type":34},"2026-04-01",{"date":88,"type":22},"2026-06-30",{"name":90,"class":41},"Uskudar University",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":16,"sex":97,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":42},"100617336","extracorporeal-shockwave-therapy-in-the-treatment-of-peyronies-disease-100617336","NCT07317297","Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease","Inclusion Criteria:\n\n* Male individuals aged 18-65 years.\n* Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months.\n* Presence of palpable penile plaque.\n\nExclusion Criteria:\n\n* Acute inflammatory stage (painful, progressive)\n* Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease.\n* Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy.\n* History of penile cancer.\n* Severe erectile dysfunction.\n* Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.","MALE","65 Years",{"count":76,"type":22},[78],"Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.",[103],"Peyronie Disease","2026-01-15",{"date":106,"type":34},"2026-01-16",{"date":108,"type":34},"2026-01-10",{"date":110,"type":22},"2026-03-30",{"name":90,"class":41},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":16,"sex":17,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100576648","multi-level-child-mental-health-interventions-in-azerbaijan-100576648","NCT06788028","Multi-level Child Mental Health Interventions in Azerbaijan","Optimizing Multi-level Interventions to Improve Child Mental Health in Azerbaijan","AZ CMH","Inclusion Criteria:\n\n1. The child is between ages 7 and 14;\n2. The child is at-risk for mental health problems as measured by one of the following criteria:\n\n   1. Elevated child emotional behavioral problems as indexed by 'high' or 'very high' scores on the Strengths and Difficulties Questionnaire (SDQ, total difficulty score or any of the four difficulty subscales - emotional, conduct, hyperactivity, or peer problems); OR\n   2. Parental risk factor - parental elevated emotional distress, as indexed by 'severe' or 'extremely severe\" score on any of the DASS-21 subscales (DASS-21 Stress = 27; Anxiety = 15; or Depression = 15);\n3. The child and parent (or other primary caregiver) can commit to study participation.\n\nIf a family has more than one eligible child, participation in the study will be offered to the older child. If both the eligible child and caregiver provide consent, they will be enrolled in the study.\n\nAll eligible children within a family can be enrolled in the study.\n\nExclusion Criteria:\n\nParticipants will be excluded from participation in the study if the child, the parent or the participating caregiver is assessed to have a cognitive impairment that would interfere with their ability to provide informed consent. This will be assessed during the consent process. As part of the informed consent process, conducted through an Azeri speaking research assistant, potential participants will also be asked to state their understanding of areas addressed during the informed consent discussion including (1) the nature and extent of participation in the study; (2) risks involved with participation; and (3) the potential benefits of participation in the study. If a participant is unable to respond to any of the three items, this youth\u002Fcaregiver pair will be excluded from the study.\n\nChildren and parents will also be excluded if one of them has significant behavioral, and\u002For mental health impairment (e.g., development disorder, autism, psychosis, high symptoms of trauma or depression) that could interfere with either with their ability to benefit from the prevention program or to participate safely. Research Assistants will ask parents about any of these conditions during the screening process.","7 Years","14 Years",{"count":123,"type":22},1200,[78],"To improve mental health outcomes among children aged 7-14 from low-income families in Azerbaijan, this study will refine and test three evidence-based intervention approaches: family-strengthening intervention; trauma-focused mental health services; and economic empowerment in the form of Child Savings Accounts.\n\nBased on prior research on the mental health of deinstitutionalized children conducted by this U.S.-Azerbaijani team in collaboration with a local Community Collaborative Board, these intervention components have been adapted to maximize fit to the cultural context of Azerbaijan. In this study, the adapted interventions will be tested with 600 child-caregiver dyads in a trial using the Multiphase Optimization Strategy (MOST) to compare different intervention components and identify the most optimal combination. Given the limited human and financial resources in low- and middle-income countries (LMICs), it will be important to identify whether each of these interventions is necessary and\u002For sufficient for improving the mental health of children.\n\nThe study will test the effects of each intervention component on children's mental health outcomes (symptoms of depression, anxiety; disruptive behaviors; post-traumatic symptoms;), on associated cognitive and social processes (e.g., attention, emotion recognition bias) and functional outcomes (e.g., academic performance). The study will also examine the mediating pathway associated with each intervention component.",[127,128,129],"Mental Health","Child Externalizing Problems","Child Behavior Problem",[131,132,133,134,135,136],"Azerbaijan","Children","Child Mental Health","Family Strengthening","Economic Empowerment","Child and Family Well-being","2025-04-03",{"date":139,"type":34},"2025-04-06",{"date":141,"type":34},"2025-03-01",{"date":143,"type":22},"2029-01-31",{"name":145,"class":41},"University of Chicago",2,""]